Grace Therapeutics

NAQ:GRCE · US00439U1043

PharmaceuticalsX-Small

360° View

Value76

Price/Sales25

Price/Earnings59

Price/Book79

Dividend Yield1

Growth39

Revenue Growth—

Profit Growth57

Capital Growth55

TSR 52w24

Safety60

Leverage86

Liquidity43

Refinancing32

Combined59

Sentiment41

Analyst Opinions100

Pro Holdings23

Opinion Changes50

Market Pulse9

Profile

CountryUSA

IndustryPharmaceuticals

SizeX-Small

TypePublic Company

ExchangeNASDAQCM

Founded2002

Employees14

Websitegracetx.com

ISINUS00439U1043

Last UpdateApr 2, 2026

Index & Theme

Pain ManagementNeurologyNeuroscienceCentral Nervous SystemBiotechnologyHealth CareMedicalPharmaceuticalTherapeutics

Description

Grace Therapeutics, Inc. engages in the development and commercialization of products for rare and orphan diseases that have the potential to improve clinical outcomes by using its novel drug delivery technologies. The company seeks to apply new pro…

Analysis

Grace Therapeutics's 360° View rank of 52 places it above its peer average — better than 52% of its true peers.

It's growing slowly (39) and looks cheap versus peers (76). On safety it is financially sound (60), and the market shows muted sentiment (41). Taken together, its Combined rank of 59 reads as above its peer average.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Grace Therapeutics with its peers

Intellia Therapeutics

NMQ:NTLA

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Ligand Pharmaceuticals

NMQ:LGND

CountryUSA

IndustryPharmaceuticals

SizeMedium

Full Stock Analysis →

Terns Pharmaceuticals

NSQ:TERN

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Fulcrum Therapeutics

NMQ:FULC

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Journey Medical Corporation

NAQ:DERM

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

MIRA Pharmaceuticals

NAQ:MIRA

—

CountryUSA

IndustryPharmaceuticals

SizeX-Small

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →